drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Fc-enhanced IgG1 anti-CTLA-4 monoclonal antibody checkpoint inhibitor that augments T-cell priming and depletes intratumoral Tregs via Fc-mediated effector functions.
nci_thesaurus_concept_id
C158557
nci_thesaurus_preferred_term
Botensilimab
nci_thesaurus_definition
An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody botensilimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. The engineered Fc domain increases the stability and half-life of the antibody.
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Fc-enhanced IgG1 monoclonal antibody that binds CTLA-4 to block inhibitory checkpoint signaling, restoring T-cell activation and priming; its engineered Fc engages FcγR-bearing effector cells to deplete intratumoral regulatory T cells, enhancing antitumor cytotoxic T-cell responses.
drug_name
Botensilimab
nct_id_drug_ref
NCT06589440